# Highmark Coding and Quality Knowledge College Rx HCCs



### Disclaimer

This presentation is the property of Highmark Inc., Highmark Health, and/or its subsidiaries ("Highmark") and is proprietary and confidential and may not be recorded in any manner including, without limitation, audio, video, photograph, screenshot, or by any other means or in any other media. Broadcasting, publication, or sharing of these materials without Highmark's express permission is strictly prohibited. This presentation is accurate as of the date it is presented but may change pursuant to regulatory requirements or in response to changing business needs. The information provided is intended to assist with support for the documentation accuracy of the diagnosis codes reported to Highmark. Providers should still reference official ICD-10-CM coding guidelines and coding manuals or electronic coding software for accurate reporting of compliant diagnosis codes. This presentation is not intended to situate Highmark as a provider of medical services or dictate the diagnosis, care, or treatment of patients. Your medical judgment remains independent with respect to all medically necessary care to your patients.

The following entities, which serve the noted regions, are independent licensees of the Blue Cross Blue Shield Association: Western and Northeastern PA: Highmark Inc. d/b/a Highmark Blue Cross Blue Shield, Highmark Choice Company, Highmark Health Insurance Company, Highmark Coverage Advantage Inc., Highmark Benefits Group Inc., First Priority Health, First Priority Life, Highmark Senior Health Company or Gateway Health Plan, Inc. d/b/a Highmark Wholecare. Central and Southeastern PA: Highmark Inc. d/b/a Highmark Blue Shield, Highmark Benefits Group Inc., Highmark Health Insurance Company, Highmark Choice Company, Highmark Senior Health Company or Gateway Health Plan, Inc. d/b/a Highmark Wholecare. Delaware: Highmark BCBSD Inc. d/b/a Highmark Blue Cross Blue Shield. West Virginia: Highmark West Virginia Inc. d/b/a Highmark Blue Cross Blue Shield, Highmark Health Insurance Company. Highmark Senior Solutions Company or Highmark Health Options West Virginia Inc. d/b/a Highmark Health Options. Western NY: Highmark Western and Northeastern New York Inc. d/b/a Highmark Blue Cross Blue Shield. Northeastern NY: Highmark Western and Northeastern New York Inc. d/b/a Highmark" in this document are references to the Highmark company that is providing the member's health benefits or health benefit administration and/or to one or more of its affiliated Blue companies.

### **HEDIS**<sup>®</sup> **Disclaimer**

HEDIS<sup>®</sup> is a registered trademark of the National Committee for Quality Assurance (NCQA). The <sup>®</sup> indicates the registered trademark symbol.

This document is for educational purpose only.

Highmark does not recommend particular treatments or health care services. This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. You should determine the appropriate treatment and follow-up with your patient. Coverage of services is subject to the terms of each member's benefit plan. Additionally, state laws and regulations governing health insurance, health plans and coverage may apply and will vary from state to state.

Reprinted with permission. For additional information about NCQA or to purchase any NCQA publications, contact NCQA Support at (888) 275-7585 or visit the NCQA website at <u>www.ncqa.org</u>



### **1. Overview of Rx HCCs**

### 2. Documentation & Coding Considerations with Examples

- Thyroid Disease
- Osteoporosis
- Hypertension
- Hyperlipidemia
- Coronary Artery Disease (CAD)
- Migraines

### **1. HEDIS Guidelines**

### 2. Other Resources

# Overview of Rx HCCs

### What are Rx HCCs?

The Prescription Drug Hierarchical Condition Category (RxHCC) risk adjustment model is a methodology used by the Centers for Medicare and Medicaid Services (CMS) to **predict a payer's expected costs of prescription drugs for their enrolled Part D members**. Members are **assigned a separate risk score for Part D** which may differ from their CMS-HCC risk score (Part C).



Many conditions are on both the CMS-HCC risk adjustment model (Part C) and Prescription Drug Hierarchical Condition Category (RxHCC) risk adjustment model; however, some conditions are only on one model.

- Conditions only on the RxHCC model are often managed through prescription drugs alone and do not require regular visits
- RxHCC only conditions are at risk of not being captured annually and not reflecting in the member's risk score.

Rx HCCs are captured through the same method as the CMS-HCC risk adjustment model.

- Medical documentation from an in person visit
- Corresponding ICD-10 code on a claim

### **Shifting Focus to Chronic Conditions**

The Prescription Drug Hierarchical Condition Category (RxHCC) risk adjustment model is significantly shifting the focus from the member's demographics to their chronic conditions. Most common conditions are treated with prescriptions, making it imperative to acknowledge them annually to ensure appropriate funds are available for members.

Osteoporosis Nearly 1 in 5 women and 1 in 20 men over the age of 50 are affected by osteoporosis.



**Thyroid Disease** An estimated 20 million Americans have some form of thyroid disease. Up to 60 percent of those with thyroid disease are unaware of their condition.



Ť

**Coronary Artery Disease** About 1 in 20 adults age 20 and older have CAD (about 5%)



**Migraine** 5% of adults in the United

States have migraine attacks in any given year.



#### Hyperlipidemia

Slightly more than half of US adults (54.5%, or 47 million people) who could benefit from cholesterol medicine are currently taking it.

**Hypertension** 

Nearly half of adults have


high blood pressure

(48.1%, 119.9 million).

https://www.cdc.gov/cholesterol/data-research/facts-stats/index.html; https://www.cdc.gov/heart-disease/data-research/facts-stats/index.html; https://www.cdc.gov/high-blood-pressure/data-research/facts-stats/index.html; https://pubmed.ncbi.nlm.nih.gov/36623287/; https://www.cdc.gov/radiation-health/data-research/facts-stats/dexa-scan.html

### The Importance of Addressing Rx HCCs

Chronic conditions, while often stable on medication, can be easily overlooked during routine assessments, especially when patients are asymptomatic. Annual wellness visits provide a critical opportunity for comprehensive medication reviews. A comprehensive review of all active prescriptions and their active associated diagnoses helps ensure a complete understanding of the patient's clinical picture.



Diligently documenting all active prescriptions and their associated active diagnoses helps paint a complete picture of the patient's health status, ensuring we accurately reflect their true burden of illness.

# **Thyroid Disease**

### **Thyroid Disease**

Thyroid disease is a general term for medical conditions where the thyroid gland doesn't produce the right amount of hormones. It affects people of all ages.


#### The two main types are:

#### Hypothyroidism (underactive thyroid)

- Under production of the thyroid hormone
- Untreated hypothyroidism can lead to high morbidity and mortality, and in children, it can cause severe mental retardation
- Prognosis is good with treatment


#### Hyperthyroidism (overactive thyroid)

- Excess production of the thyroid hormone
- Untreated hyperthyroidism can lead to complications such as atrial fibrillation, congestive heart failure, or osteoporosis
- Prognosis is good with treatment



## Hypothyroidism vs Hyperthyroidism

#### Hypothyroidism



Hyperthyroidism

### **Use of Thyroid Medications**

Treatment for conditions cannot be assumed based solely on a medication list. Therefore, it is important to annually assess the patient's hypothyroidism or hyperthyroidism and to confirm the diagnosis, even if they are asymptomatic.

#### Hyperthyroidism

**propylthiouracil** (PTU)

#### methimazole

(Tapezole)

#### Hypothyroidism

levothyroxine

(Synthroid, Levothyroid, Levoxyl)

#### liothyronine

(Cytomel)

#### liotrix

(Thyrolar)

#### natural thyroid

(Armour Thyroid, Nature-thyroid, Westhroid)





Highmark Inc. CONFIDENTIAL AND PROPRIETARY

### **Thyroid Disease Documentation Considerations**

**Document the patient's symptoms**, including any weight gain or loss, changes in appetite, heat or cold intolerance, sweating, palpitations, or fatigue. **Note any relevant physical exam findings**, such as skin changes, neurological changes, eye bulging, goiter, and heart rate irregularities (e.g., arrhythmias).

**Determine the etiology of thyroid dysfunction**. If secondary to another medical condition, specify the primary cause.



**Record and interpret the results of relevant thyroid function tests**, including TSH, FT4, FT3, thyroid antibodies, as well as imaging studies such as thyroid scans or ultrasounds. **Ensure documentation reflects the clinical significance of these findings.** 

**Document the complete treatment plan**, including specific treatment goals, scheduled follow-up appointments, and any referrals made. Also, **link all medications prescribed**, record the name, dosage, and current status (i.e., whether the medication is active or discontinued).

### **Thyroid Disease ICD-10-CM Codes**

For complete codes and all applicable coding instructions, refer to the current ICD-10-CM Alphabetic Index and Tabular List.

	Hypothyroidism		Hyperthyroidism 5 <sup>th</sup> Character		
E02	Subclinical iodine-deficiency hypothyroidism	-	0 – without thyrotoxic crisis or storm 1 – with thyrotoxic crisis or storm		
E03.0	Congenital hypothyroidism with diffuse goiter	E05.0_	Thyrotoxicosis with diffuse goiter		
E03.1	Congenital hypothyroidism without goiter	E05.1_	Thyrotoxicosis with toxic single thyroid nodule		
E03.2	Hypothyroidism due to medicaments and other exogenous substances	E05.2_	Thyrotoxicosis with toxic single thyroid nodule		
E03.3	Postinfectious hypothyroidism	E05.3_	Thyrotoxicosis with toxic multinodular goiter		
E03.8	Other specified hypothyroidism	E05.4_	Thyrotoxicosis factitia		
E03.9	Hypothyroidism, unspecified	E05.8_	Other thyrotoxicosis		
E89.0	Postprocedural hypothyroidism	E05.9_	Thyrotoxicosis, unspecified		

## Hypothyroidism Example



#### HPI:

63-year-old female here for AWV. She had her blood work done last week. She **is currently asymptomatic** and still very active with no issues of fatigue. **Thyroid levels have been stable**.

#### Labs:

TSH 3.8 uIU/mL , Free T4 1.2 ng/dL

#### Meds:

Levothyroxine 50mcg once daily

#### **Assessment & Plan:**

Hypothyroidism, unspecified – Patient currently asymptomatic **on Levothyroxine**. **Labs reviewed and WNL**, follow up labs in 3 months to recheck thyroid levels

Provider documented the current asymptomatic status of the patient, reviewed the TSH/Free T4 test results interpreting as within normal limits and addressed the medication management with Levothyroxine.

Based on the documentation in the note, it is appropriate to code Hypothyroidism, unspecified E03.9

Osteoporosis

### Osteoporosis

Osteoporosis is a condition characterized by low bone mineral density and altered bone microstructure, which increases the risk of fragility fractures from low-impact activities.



With early detection and treatment, the prognosis is generally favorable; however, untreated cases can result in chronic pain and fractures. Hip and spinal fractures represent the most serious potential complications. Osteoporosis, a "silent" disease often only noticeable after a fracture, weakens bones, increasing fracture risk.



Weakened by osteoporosis, bones can fracture from simple actions like coughing or minor falls

Osteoporosis can affect anyone at any age, though the risk increases with age and is **more common in women than men.** 





Osteoporosis screening recommended for women over 65 or with risk factors

Bone mineral density is most commonly measured with a dualenergy x-ray absorptiometry (DXA scan).

> Treatment Options: Nutrition Lifestyles changes Exercise Fall prevention Medications

### **Medication Use in Osteoporosis**

#### Common Osteoporosis Medications

#### **Bisphosphonates**

- alendronate (*Fosamax*)
- risendronate (Actonel, Atelvia)
- Ibandronate
- zoledronic acid (*Reclast*)

#### **Bone building**

- teriparatide (Forteo)
- abaloparatide (Tymlos)
- romosozumab (Evenity)

#### Denosumab (Prolia)

Hormone replacement therapy (HRT) or estrogen therapy Effective management of osteoporosis medications requires a thorough medication list review at each patient encounter.

Be sure to document the following to ensure accurate patient records:

- Any newly prescribed medications
- □ All dosage adjustments
- Discontinued medications

### **Coding & Documentation Considerations**

#### Osteoporosis

For complete codes and all applicable coding instructions, refer to the current ICD-10-CM Alphabetic Index and Tabular List.

M08.0	Age-related osteoporosis with current pathological fracture
M80.8	Other osteoporosis with current pathological fracture
M81.0	Age-related osteoporosis without current pathological fracture
M81.6	Localized osteoporosis
M81.8	Other osteoporosis without current pathological fracture

#### Specify the type

• Age related, diffuse, drug related, localized, or postmenopausal

#### Assess the risk factors

• Age, family history, dietary history, lifestyle, fall history, and medical conditions


#### Document the presence of a pathological fracture and location

• Femur, ilium, pelvis, or vertebra

#### Provide the status of the fracture

• Routine, delayed healing, nonunion, or malunion

#### Interpret testing results and document the care plan



### **Osteoporosis Example**



Fracture presence documented



Treatment linked to condition



Assessment documented to the highest level of specificity

#### Subjective:

58-year-old female in today for **follow up care of her fractured foot** sustained in a fall last month. She seems to be healing nicely with no complaints and is looking forward to getting her cast off.

Medication List: Reclast

#### **Assessment & Plan:**

Age-related Osteoporosis with current pathological fracture right foot with routine healing (ICD–10 code M80.071D) Continue Reclast for bone health. Reviewed fall prevention and Scheduled cast removal in 4 weeks.

In the Assessment & Plan, the provider documented the presence of the fracture, its treatment, and the patient's osteoporosis with the highest level of specificity. Based on the note's documentation, it is appropriate to code M80.071D for the diagnosis of age-related osteoporosis with current pathological fracture of the right ankle and foot, with routine healing, subsequent encounter for fracture with routine healing. Hypertension

### Hypertension

Hypertension, also referred to as high blood pressure, is a prevalent medical condition characterized by elevated pressure within the arteries.

#### **Blood Pressure Categories**

- Normal blood pressure ≤ 120/80
- Elevated blood pressure 120-129/<80
- **Stage 1** hypertension 130-139/80-89
- Stage 2 hypertension ≥140/≥90

Blood pressure exceeding 180/120 mmHg constitutes a hypertensive emergency or crisis

https://www.heart.org/en/health-topics/high-blood-pressure/understanding-blood-pressure-readings


Management and prevention of hypertension can be achieved through adherence to medications, healthy lifestyle practices, including regular exercise, a balanced diet, and smoking cessation.

If untreated, hypertension can significantly increase the probability of adverse health events, such as myocardial infarction (heart attack), cerebrovascular accident (stroke), and other related complications.

### **Medication Use in Hypertension**

The patient's blood pressure should be checked annually, and any medications prescribed for its management should be linked and documented.


Apha blockers	doxazosin, prazosin, terazosin		
Angiotensin II receptor blockers	candesartan, losartan, valsartan		
Angiotensin converting enzyme	captopril, enalapril, fosinopril, lisinopril		
Beta blockers	atenolol, bisoprolol, nebivolol, pindolol		
Calcium channel blockers	amlodipine, diltiazem, felodipine		
Diuretics	Lasix, bumex, demadex, Midamor		
Vasodilators	hydralazine, minoxidil		



Highmark Inc. CONFIDENTIAL AND PROPRIETARY


### **Hypertension Documentation Considerations**

When documenting hypertension, it's important to include the following information:



### **Hypertension ICD-10-CM Codes**

For complete codes and all applicable coding instructions, refer to the current ICD-10-CM Alphabetic Index and Tabular List.



### **Hypertension Example**





**BP Monitoring/ Lab** results reviewed



Condition documented with treatment linked

#### Subjective:

Patient here today for f/u of HTN with no complaints. Reports consistent medication adherence with Amlodipine and Losartan and following **heart healthy diet low in sodium**.

Vital Signs: BP 128/82

#### Labs:

eGFR 92 mL/min/1.73m2, Creatinine 0.9 mg/dL, Sodium 141 mEq/L

#### **Assessment & Plan:**

Essential Hypertension – BP well controlled. No complications. Labs WNL indicating good kidney function/sodium control. Cont Losartan 100mg PO daily and Amlodipine 5mg PO daily. Addressed importance of daily BP monitoring, lifestyle modifications, low-sodium diet and regular exercise. F/U in 3 months for BP check and med review.

The provider addressed the status of the hypertension, noting it was well-controlled. They are monitoring for complications, reviewed blood pressure and laboratory findings, and linked the treatment to the condition. Based on the documentation in the note, it is appropriate to code Essential Hypertension I10. Hyperlipidemia


## Hyperlipidemia

Hyperlipidemia, or high cholesterol, is a lifelong condition characterized by elevated levels of lipids (fats), including cholesterol and triglycerides, in the blood. While it requires ongoing management, treatment can effectively control hyperlipidemia and minimize its risks. Untreated, it can lead to severe vascular disease and even death. Because hyperlipidemia often presents without symptoms until significant damage occurs, routine check-ups and adherence to risk assessment guidelines are essential for early detection and proactive management.

#### Types:

- Pure hypercholesterolemia
- Familial hypercholesterolemia
- Pure hyperglyceridemia
- Mixed hyperlipidemia

Diagnosis usually involves a lipid panel blood test. Treatment includes lifestyle changes, medication, and aims to reduce the risk of heart attacks and strokes.



### **Coding & Documentation Considerations**

Since patients may not *require* frequent office visits for management, it's important to emphasize the necessity of yearly check-ups so the condition and patient's adherence to standards can be tracked to minimize the risk of it not being captured.



#### Specify the type

- E78.00 Pure hypercholesterolemia, unspecified
- E78.01 Familial hypercholesterolemia
- E78.1 Pure hyperglyceridemia
- E78.2 Mixed hyperlipidemia
- E78.49 Other hyperlipidemia
- E78.5 Hyperlipidemia, unspecified



### Document any coexisting conditions

- Diabetes
- Hypertension
- Coronary Artery Disease
- Hypothyroidism
- Kidney disease
- Liver disease

Highmark Inc. CONFIDENTIAL AND PROPRIETARY



#### Record any contributing lifestyle factors

- Diet
- Physical activity level
- Smoking status
- Alcohol and drug use



Document the care plan, including listing supporting evidence such as lab results, and linking medications prescribed for management

ACLY inhibitors	bempedoic acid		
Bile acid sequestrants	colestipol, cholestyramine		
Fibrates	gemfibrozil, fenofibrate		
Omega-3 fatty acids	Lovaza, Vascepa, Epanova		
PCSK9 inhibitors	alirocumab, evolocumab		
Statins	atorvastatin, fluvastatin		
Other	Ezetimibe, Niacin (B vitamin)		

## Hyperlipidemia Example



**Documented co**existing conditions and life-style factors



\_abs ordered for monitoring



documented with treatment linked

#### Subjective:

Patient here to establish care. She just moved here 6 months ago. She has H/O CVA, HLD and HTN. Last blood work was completed 2 years. She denies smoking and alcohol use. She needs a new script for her meds.

Medication List: Simvastatin 20mg Evolocumab 140 mg SC q2wk

#### **Assessment & Plan:**

Hyperlipidemia – Ordered Lipid Panel, CBC and CMP. Cont Simvastatin and Evolocumab, order sent to new pharmacy. Discussed maintaining a healthy active lifestyle and continuing abstinence from smoking and alcohol.

Provider has documented the primary condition along with coexisting conditions and discussed life-style factors. Labs and medications have been ordered for effective management. Based on the documentation in the note, it is appropriate to code Hyperlipidemia unspecified E78.5.

# Coronary Artery Disease

### **Coronary Artery Disease**

https://my.clevelandclinic.org/health/diseases/16898-coronary-artery-disease

Coronary artery disease (CAD) is a common condition where the arteries supplying blood to the heart narrow due to plaque buildup. This can lead to reduced blood flow and, over time, may cause symptoms like chest pain (angina) or shortness of breath (dyspnea).

#### There are two main forms of CAD:

#### Stable ischemic heart disease (chronic form)

• Arteries gradually narrow, causing manageable symptoms

#### Acute coronary syndrome (sudden, emergency situation)

 A blood clot blocks blood flow, potentially leading to a heart attack.

Complications from CAD can include heart rhythm issues (arrhythmias), cardiac arrest, cardiogenic shock, and heart failure. Diagnosis involves physical exams and tests. Treatment focuses on lifestyle changes, medications, and potentially procedures or surgery.

# **Use of Medications in CAD**

Coronary artery disease is commonly asymptomatic which increases the risk of not being assessed on an annual basis.

To prevent this from occurring, providers should assess coronary artery disease (CAD) at least annually

Remember to review the medication list and update it as needed at each visit, especially when:

- A new prescription is given
- Change in dosage
- Medication is stopped

#### **Commonly Used Medications**

ACE inhibitors	benazepril, captopril, enalapril, fosinopril, lisinopril, quinapril, ramipril	
Angiotensin receptor blockers	candesartan, losartan, telmisartan	
Beta blockers	atenolol, bisoprolol, carvedilol, metoprolol	
Calcium channel blockers	verapamil, diltiazem, amlodipine, nifedipine	
Glycoprotein IIb/IIIa inhibitors	abciximab, eptifibatide, tirofiban	
Thrombolytics	alteplase, reteplase, streptokinase, tenecteplase	
Other	antiplatelets, anticoagulants, morphine, nitrates, statins	

### **Documentation Considerations**


Coronary artery disease is commonly asymptomatic which increases the risk of not being assessed on an annual basis.

To prevent this from occurring, providers should assess coronary artery disease (CAD) at least annually.

Remember to review the medication list and update it as needed at each visit, especially when:

- A new prescription is given
- Change in dosage
- Medication is stopped

n	Medications	ACE inhibitors	benazepril, captopril, enalapril, fosinopril, lisinopril, quinapril, ramipril		
mme		Angiotensin receptor blockers	candesartan, losartan, telmisartan		
ပိ		Other	antiplatelets, anticoagulants, calcium channel blockers, morphine, nitrates, statins		



- Specify the cause Lipid rich plaque, calcified coronary lesion
- Document angina, if present Angina pectoris, unstable, documented spasm, refractory
- Link the treatment to the condition Lifestyle changes, medications, procedures
- Include supporting evidence Imaging results, lab results, specialist's notes

### **Coronary Artery Disease ICD-10-CM Codes**

Atherosclerosis of Coronary Artery (CAD)						
Native artery		Autologous artery bypass graft(s)		Bypass graft of transplanted heart		
12510	Without angina	125720	With unstable angina	125760	With unstable angina	
125110	With unstable angina	125721	With angina & documented spam	125761	With angina & documented spam	
125111	With angina & documented spam	125722	With refractory angina	125762	With refractory angina	
125112	With refractory angina	125728	With other forms of angina	125768	With other forms of angina	
125118	With other forms of angina	125729	With unspecified angina	125769	With unspecified angina	
125119	With unspecified angina	Nonau	tologous biological bypass graft(s)	Other	bypass graft(s)	
Bypas	s graft(s), unspecified	125730	With unstable angina	125790	With unstable angina	
125700	With unstable angina	125731	With angina & documented spam	125791	With angina & documented spam	
125701	With angina & documented spam	125732	With refractory angina	125792	With refractory angina	
125702	With refractory angina	125738	With other forms of angina	125798	With other forms of angina	
125708	With other forms of angina	125739	With unspecified angina	125799	With unspecified angina	
125709	With unspecified angina	Native	artery of transplanted heart	Other	coronary vessels without angina	
Autolo	gous vein bypass graft(s)	125750	With unstable angina	125810	Bypass graft(s)	
125710	With unstable angina	125751	With angina & documented spam	125811	Native artery of transplanted heart	
125711	With angina & documented spam	125752	With refractory angina	125812	Bypass graft of transplanted heart	
I25712 With refractory angina		125758	With other forms of angina	This is not an exhaustive list of conditions.		
I25718With other forms of angina		125759	59 With unspecified angina		Please refer to the current ICD-10-CM for	
125719 With unspecified angina				coding instructions and any condition not listed here.		

Coding and Quality Knowledge College | January 2025

### **Coronary Artery Disease Example**



Annual assessm completed



Treatment linked to condition



Condition documented to highest level of specifity

#### Subjective:

Here for annual visit, with **known CAD**. She **follows with Cardio** every 6 months. Compliant with her Brilinta and ASA. Other than CAD, she remains healthy and active. Lifelong non-smoker.

#### **Past Medical History:**

CAD – non-obstructive, diagnosed several years ago via cardiac cath

#### **Physical Exam:**

Cardiovascular: Denies CP, SOB or palpitations. RRR

#### **Assessment & Plan:**

Atherosclerotic heart disease of native coronary artery without angina pectoris – Cont low dose ASA and Brilinta. Asx. Following with Cardiology.

Provider performed an annual assessment of the patient's CAD, evaluated for signs and symptoms, linked the treatment and documented to the highest level of specificity. Based on the documentation in the note, it is appropriate to code Atherosclerotic heart disease of native coronary artery without angina pectoris I25.10. Migraine

# **Migraine Diagnosis vs Medication**

DOS 2023		i <b>graine Medications</b> imovig Emgality jovy Qulipta	375,538 Members	<b>Prevalence</b> <ul> <li>Headache (4.9%)</li> <li>Migraine (2.7%)</li> <li>Both Dx (.08%)</li> </ul>			
	Members on a Migraine Medication						
Headache Dx	Migraine Dx	Both Dx	Non-Headache Dx	Total			
110	3,389	53	8,086	11,638			

- 29% of members have an associated migraine diagnosis linked to their migraine medication
- 69% of members do not have an associated migraine diagnosis captured despite being on a migraine medication which may indicate a low recapture rate
- Members on a migraine medication with an **associated headache diagnosis may indicate possible** undercoding
- Providers documenting the presence of both a headache and migraine diagnosis while on a migraine medication may indicate an unclear diagnosis presentation

# **Use of Migraine Medications**

#### Abortive

Taken during migraine attacks to stop symptoms

Anti-inflammatories ASA, naproxen, Ibuprofen, diclofenac, ketorolac

#### **Triptans**

sumatriptan, zolmitriptan, rizatriptan, eletriptan, naratriptan

#### Antiemetics

metoclopramide, prochlorperazine, chlorpromazine

#### **Ergotamines**

dihydroergotamine



#### **Preventive** Taken to reduce the severity or frequency

#### **Beta-blockers**

propranolol, timolol, bisoprolol, metoprolol, atenolol, nadolol

#### **Calcium channel blockers** verapamil (off-label, most commonly used)


Antidepressants amitriptyline, fluoxetine

Antiepileptics topiramate, valproate

Follow-up and reassessment of treatments are necessary on an ongoing basis, even after a solid plan is implemented. Remember to review and update the medication list as needed at each visit.

https://www.mayoclinic.org/diseases-conditions/migraine-headache/diagnosis-treatment/drc-20360207

# **Migraine Documentation Considerations**



**MIGRAINE TYPES:** Abdominal (in children), Chronic, Hemiplegia, Menstrual, Silent (without headache), Retinal (ocular), Status migrainosus

**MIGRAINE TRIGGERS:** Alcohol, Weather changes, Lack of sleep, Schedule changes, Dehydration, Hunger, Certain Foods, Strong smells, Teeth grinding at night, Menstruation

Coding and Quality Knowledge College | January 2025

Migraine ICD-10 Codes					
Migraine without aura		Persistent migraine aura with cerebral infarction			
G43001	Not intractable, with status migrainosus	G43601	Not intractable, with status migrainosus		
G43009	Not intractable, without status migrainosus	G43609	Not intractable, without status migrainosus		
G43011	Intractable, with status migrainosus	G43611	Intractable, with status migrainosus		
G43019	Intractable, without status migrainosus	G43619	Intractable, without status migrainosus		
Migraine with aura		Chronic migraine without aura			
G43101	Not intractable, with status migrainosus	G43701	Not intractable, with status migrainosus		
G43109	Not intractable, without status migrainosus	G43709	Not intractable, without status migrainosus		
G43111	Intractable, with status migrainosus	G43711	Intractable, with status migrainosus		
G43119	Intractable, without status migrainosus	G43719	Intractable, without status migrainosus		
Hemiple	Hemiplegic migraine		nigraine with aura		
G43401	Not intractable, with status migrainosus	G43E01	Not intractable, with status migrainosus		
G43409	Not intractable, without status migrainosus	G43E09	Not intractable, without status migrainosus		
G43411	Intractable, with status migrainosus	G43E11	Intractable, with status migrainosus		
G43419	Intractable, without status migrainosus	G43E19	Intractable, without status migrainosus		
Persiste	nt migraine aura without cerebral infarction	Menstru	al migraine		
G43501	Not intractable, with status migrainosus	G43821	Not intractable, with status migrainosus		
G43509	Not intractable, without status migrainosus	G43829	Not intractable, without status migrainosus		
G43511	Intractable, with status migrainosus	G43831	Intractable, with status migrainosus		
G43519	Intractable, without status migrainosus	G43839	Intractable, without status migrainosus		

Migraine ICD-10 Codes					
Other m	igraine	Cyclical	vomiting, in migraine		
G43801	Not intractable, with status migrainosus	G43A0	Not intractable		
G43809	Not intractable, without status migrainosus	G43A1	Intractable		
G43811	Intractable, with status migrainosus	Ophthal	moplegic migraine		
G43819	Intractable, without status migrainosus	G43B0	Not intractable		
Migraine	e unspecified	G43B1	Intractable		
G43901	Not intractable, with status migrainosus	Abdomi	nal migraine		
G43909	Not intractable, without status migrainosus	G43D0	Not intractable		
G43911	Intractable, with status migrainosus	G43D1	Intractable		
G43919	Intractable, without status migrainosus				

# **Migraine Example**

Symptoms, location and how it started







**Specified** as migraine with treatment linked

#### **History of Present Illness:**

Presenting today with a **severe pounding headache** that **came** on suddenly, with pain on the left, started about 5 hours ago. Describes the headache as **bothersome to her eyes**. Patient states these occur approximately every 3-4 months.

#### **Assessment & Plan:**

Migraine without aura, not intractable, without status **migrainosus** – Typical migraine headache, without aura. Frequency of headaches (every 3-4 months) does not warrant prophylactic medication at this time. Imitrex 50mg tablet – Take one tablet orally at onset. May repeat once in 2 hours if needed. Do not exceed 200mg in 24 hours. Medication education provided. F/U if headaches become more frequent, severe, or unresponsive to meds. Keep headache diary.

Provider thoroughly assessed the patient's headache, including symptoms, location, onset, and pain level, leading to a diagnosis of migraine and a corresponding treatment plan. Based on the documentation in the note, it is appropriate to code Migraine without aura, not intractable, without status migrainosus G43.009.

# **HEDIS Guidelines**

### **Defining Frailty and Advanced Illness Criteria for Member Exclusion**

Members 66–80 years of age as of December 31 of the measurement year with frailty **and** advanced illness. Members must meet **<u>both</u>** frailty and advanced illness criteria to be excluded:

**Frailty** – At least two indications of frailty with different dates of service during the measurement year

**Advanced Illness** – Either of the following during the measurement year or the year prior to the measurement year:

- Advanced illness on at least two different dates of service
- Members 81 years of age and older as of December 31 of the measurement year with at least two indications of frailty with different dates of service during the measurement year
- Dispensed dementia medication

#### **Dementia Medications**

Cholinesterase inhibitors (include, but not limited to): Donepezil, Galantamine, Rivastigmine Miscellaneous central nervous system agents (include, but limited to): Memantine Dementia combinations (include, but not limited to): Donepezil-memantine

### **Controlling High Blood Pressure (CBP)**

The percentage of members 18-85 years of age who had a diagnosis of hypertension (HTN) and whose blood pressure (BP) was adequately controlled (<140/90 mm Hg) during the measurement year.

#### **Tips to Help Close Member Care Gaps:**

**NOTE:** Look for the patient's most recent BP (systolic and diastolic) in the measurement period.

- The BP reading must occur on or after the date when the second diagnosis of hypertension.
- The member is numerator compliant if the BP is <140/90 mm Hg.
- The member is not compliant if the BP is ≥140/90 mm Hg.
- If there are multiple BPs on the same date of service, use the lowest systolic and lowest diastolic BP on that date as the representative BP.
- BP readings taken by the member and documented in the member's medical record are eligible for use in reporting (provided the BP does not meet any exclusion criteria). There is no requirement that there be evidence the BP was collected by a PCP or specialist.
- BP readings are acceptable via telephone visits, e-visits, and/or virtual check-ins. Documentation **must** include a date of service.
- BP readings can be taken from any digital device.
- Ranges and thresholds do not meet criteria for this measure.
- RETAKE: During office visits, if the initial BP reading is outside of the acceptable range, retake during the visit. If the second reading is compliant use the appropriate code to bill for that BP.

### **Controlling High Blood Pressure (CBP) cont.**

#### **Required Exclusions:**

- Members who use hospice services or elect to use a hospice benefit any time during the measurement year
- Members receiving palliative care any time during the measurement year.
- Members who had an encounter for palliative care any time during the measurement year
- Members with a diagnosis that indicates end-stage renal disease any time during the member's history on or prior to December 31 of the measurement year.
- Diagnostic or therapeutic procedures that require a medication regimen, a change in diet or a change in medication are eligible for exclusion including
- Members with a procedure that indicates ESRD: dialysis, nephrectomy, or kidney transplant any time during the member's history on or prior to December 31 of the measurement year.
- Members with a diagnosis of pregnancy any time during the measurement year
- Medicare members 66 years of age and older as of December 31 of the measurement year who meet either of the following:
  - > Enrolled in an Institutional SNP (I-SNP) any time during the measurement year.
  - > Living long-term in an institution any time during the measurement year
- Members 66–80 years of age as of December 31 of the measurement year with frailty and advanced illness.
   Members must meet **both** frailty and advanced illness criteria to be excluded:
- Members 81 years of age and older as of December 31 of the measurement year with at least two indications of frailty

### **Controlling High Blood Pressure (CBP) cont.**

#### Codes include but not limited to:

CPT II Codes:

- 3074F Systolic <130
- 3075F Systolic 130-139
- 3078F Diastolic <80
- 3079F Diastolic 80-89

#### ICD10: ESSENTIAL HYPERTENSION

• 110

SNOWMED CODES:

 1201005, 23717007, 35303009, 63287004, 59621000, 18416000, 78808002, 9901000, 72022006, 19769006, 371125006, 46481004, 78975002, 40511000119107, 429457004

### **Blood Pressure Control for Patients with Hypertension (BPC-E)**

The percentage of members 18-85 years of age who had a diagnosis of hypertension (HTN) and whose blood pressure (BP) was adequately controlled (<140/90 mm Hg) during the measurement year.

**Clinical Recommendation Statement:** The American Academy of Family Physicians (AAFP) strongly recommends clinicians treat adults who have hypertension to a standard blood pressure target (<140/90 mm Hg) to reduce the risk of all-cause and cardiovascular mortality.

#### Tips to Help Close Member Care Gaps:

- Members who are 18-85 years old as of the last day of the measurement period who meet either of the following criteria:
  - > At least two outpatient visits, telephone visits, e-visits or virtual check-ins on different dates of service with a diagnosis of hypertension on or between January 1 of the year prior to the measurement period and June 30 of the measurement period.
  - > At least one outpatient visit, telephone visit, e-visit or virtual check-in with a diagnosis of hypertension and at least one dispensed antihypertensive medication on or between January 1 of the year prior to the measurement period and June 30 of the measurement period.
- Do not include BPs taken in an acute inpatient setting or ED visit. If there are multiple BPs on the same date of service, use the last BP reading on that date as the representative BP.
- The member is numerator compliant if the representative BP is <140/90 mm Hg. The member is not compliant if the BP is ≥140/90 mm Hg, if there is no BP reading during the measurement period or if the reading is incomplete (e.g., the systolic or diastolic level is missing).

### **Blood Pressure Control for Patients with Hypertension (BPC-E) cont.**

#### Codes include but not limited to:

CPT II Codes:

- 3074F Systolic <130
- 3075F Systolic 130-139
- 3078F Diastolic <80
- 3079F Diastolic 80-89

#### ICD10: ESSENTIAL HYPERTENSION

• 110

#### SNOWMED CODES:

 1201005, 23717007, 35303009, 63287004, 59621000, 18416000, 78808002, 9901000, 72022006, 19769006, 371125006, 46481004, 78975002, 40511000119107, 429457004

### Persistence of Beta-Blocker Treatment After a Heart Attack (PBH)

The percentage of members 18 years of age and older during the measurement year who were hospitalized and discharged from July 1 of the year prior to the measurement year to June 30 of the measurement year with a diagnosis of AMI and who received persistent beta-blocker treatment for 180 days (6 months) after discharge.

#### Tips to Help Close Member Care Gaps:

- <u>Treatment days</u> (covered days) The actual number of calendar days covered with prescriptions within the specified 180-day measurement interval (e.g., a prescription of a 90-day supply dispensed on the 100th day will have 81 days counted in the 180-day interval).
- <u>180-day measurement interval</u> The 180-day period that includes the discharge date and the 179 days after discharge
- <u>Event/diagnosis</u> An acute inpatient discharge from July 1 of the year prior to the measurement year through June 30 of the measurement year with any diagnosis of AMI on the discharge claim. To identify an acute inpatient discharge:
  - > Identify all acute and nonacute inpatient stays (Inpatient Stay Value Set).
  - > Exclude nonacute inpatient stays (Nonacute Inpatient Stay Value Set).
  - > Identify the discharge date for the stay.
- <u>Anchor date Discharge date</u>

**NOTE:** If a member has more than one episode of AMI that meets the event/diagnosis criteria, from July 1 of the year prior to the measurement year through June 30 of the measurement year, include **only the first discharge**.

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA). Coding and Quality Knowledge College | January 2025

### Persistence of Beta-Blocker Treatment After a Heart Attack (PBH) cont.

#### Tips to Help Close Member Care Gaps: cont.

#### **Beta Blocker Medications**

Description	Prescription			
Noncardioselective beta-	Carvedilol	Pindolol	Timolol	
blockers	Labetalol	Propranolo	• Sotalol	
	Nadolol			
Cardioselective beta-blockers	Acebutolol	Betaxolol	Metoprolol	
	Atenolol	Bisoprolol	<ul> <li>Nebivolol</li> </ul>	
Antihypertensive combinations	Atenolol-chlorthalidone		<ul> <li>Hydrochlorothiazide-metoprolol</li> </ul>	
	<ul> <li>Bendroflumethiazide-nadolol</li> </ul>		<ul> <li>Hydrochlorothiazide-propranolol</li> </ul>	
	Bisoprolol-hydrochlorothiazide			

### Persistence of Beta-Blocker Treatment After a Heart Attack (PBH) cont.

**Required Exclusions:** Exclude members who meet any of the following criteria:

- Members who use hospice services or elect to use a hospice benefit any time during the measurement year.
- Members who die any time during the measurement year.
- Members with a medication dispensing event that indicates a contraindication to beta-blocker therapy (see Asthma Exclusions Medications List) any time during the member's history through the end of the continuous enrollment period.
- Members with a **diagnosis** that indicates a contraindication to beta-blocker therapy any time during the member's history through the end of the continuous enrollment period meet criteria.
- Medicare members 66 years of age and older as of December 31 of the measurement year who meet either of the following:
  - > Enrolled in an Institutional SNP (I-SNP) any time on or between July 1 of the year prior to the measurement year and the end of the measurement year
  - Living long-term in an institution any time on or between July 1 of the year prior to the measurement year and the end of the measurement year
  - Members 66–80 years of age as of December 31 of the measurement year with frailty and advanced illness. Members must meet both frailty and advanced illness criteria to be excluded (see Dementia Medication List)
  - Members 81 years of age and older as of December 31 of the measurement year with at least two indications of frailty with different dates of service any time on or between July 1 of the year prior to the measurement year and the end of the measurement year.

# **HEDIS<sup>®</sup>** Measures

### Persistence of Beta-Blocker Treatment After a Heart Attack (PBH) cont.

#### **Required Exclusions: Medications**

#### **Asthma Exclusions Medications**

- Bronchodilator combinations
  - > Budesonide-formoterol, Fluticasone-vilanterol, Fluticasone-salmeterol, Formoterol-mometasone
- Inhaled corticosteroids
  - > Beclomethasone, Budesonide, Ciclesonide, Flunisolide, Fluticasone, Mometasone

#### **Dementia Exclusions Medications**

- Cholinesterase inhibitors
  - Donepezil, Galantamine, Rivastigmine
- Miscellaneous central nervous system agents
  - > Memantine
- Dementia combinations
  - Donepezil-memantine

#### Codes include but not limited to:

ICD10: I21.01, I21.02, I21.09, I21.11, I21.19, I21.21, I21.29, I21.3, I21.4, I21.B SNOMED: 57054005, 194809007, 233838001, 70422006, 233835003 Claims – based for HEDIS<sup>®</sup> Pharmacy Data

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA). Coding and Quality Knowledge College | January 2025

### Statin Therapy for Patients with Cardiovascular Disease (SPC)

The percentage of males 21–75 years of age and females 40–75 years of age during the measurement year who were identified as having clinical atherosclerotic cardiovascular disease (ASCVD) and met the following criteria. The following rates are reported:

- *1. Received Statin Therapy.* Members who were dispensed at least one high-intensity or moderateintensity statin medication during the measurement year.
- 2. Statin Adherence 80%. Members who remained on a high-intensity or moderate-intensity statin medication for at least 80% of the treatment period.

#### Tips to Help Close Member Care Gaps:

<u>IPSD</u> (Index prescription start date) – The earliest prescription dispensing date for any statin medication of at least moderate intensity during the measurement year.

<u>Treatment period</u> – The period of time beginning on the IPSD through the last day of the measurement year. <u>PDC</u> – Proportion of days covered. The number of days the member is covered by at least one statin medication prescription of appropriate intensity, divided by the number of days in the treatment period.

- Members are identified for the eligible population in two ways: by event or by diagnosis but a member only needs to be identified by one method to be included in the measure.
  - > Event MI, CABG, PCI, other revascularization
  - Diagnosis members who had at least one encounter with a diagnosis of IVD during both the measurement year and the year prior to the measurement year. An outpatient visit, telephone visit, evisit wirtug a base of the set of the measurement year.
  - visit, virtual check-in or acute inpatient encounter with an IVD diagnosis
  - > At least one acute inpatient discharge with an IVD diagnosis on the discharge claim

### Statin Therapy for Patients with Cardiovascular Disease (SPC) cont.

#### Tips to Help Close Member Care Gaps: cont.

- Members are identified for the eligible population in two ways: by event or by diagnosis
   Event Any of the following during the year prior to the measurement year meet criteria:
  - *MI* Discharged from an inpatient setting with an MI on the discharge claim
    - $\succ$  Identify the discharge date for the stay.
    - Identify all acute and nonacute inpatient stays
  - CABG Members who had CABG in any setting
  - *PCI* Members who had PCI in any setting
  - Other revascularization Members who had any other revascularization procedures in any setting **Diagnosis** Identify members who had at least one encounter with a diagnosis of IVD during both the measurement year and the year prior to the measurement year. The following encounters meet criteria.
  - An outpatient visit, telephone visit, e-visit, virtual check-in or acute inpatient encounter with an IVD diagnosis
  - At least one acute inpatient discharge with an IVD diagnosis on the discharge claim
    - Identify all acute and nonacute inpatient stays
    - Exclude nonacute inpatient stays
    - > Identify the discharge date for the stay

### Statin Therapy for Patients with Cardiovascular Disease (SPC) cont.

#### Tips to Help Close Member Care Gaps: cont.

- Educate on the importance of complying with statin therapy during every communication
- If member has intolerance or side effects such as myalgias, if clinically appropriate consider a different statin that is hydrophilic (e.g., rosuvastatin or pravastatin)
- A lower dose than previously tried
- Reducing the frequency- simplify the medication regime by using once-daily dosage if possible
- Review the patient's medication list during each visit
- Routinely arrange the next appointment for consistent follow-up and monitoring

#### **Required Exclusions:**

- Members with a diagnosis of pregnancy during the measurement year or the year prior to the measurement year
- In vitro fertilization in the measurement year or the year prior to the measurement year.
- Dispensed at least one prescription for clomiphene during the measurement year or the year prior to the measurement year.
- ESRD during the measurement year or the year prior to the measurement year
- Dialysis during the measurement year or the year prior to the measurement year.
- Cirrhosis during the measurement year or the year prior to the measurement year
- Myalgia, myositis, myopathy or rhabdomyolysis during the measurement year
- Myalgia or rhabdomyolysis caused by a statin any time during the member's history through December 31 of the measurement year.

### Statin Therapy for Patients with Cardiovascular Disease (SPC) cont.

#### **Required Exclusions: cont.**

- Members who use hospice services or elect to use a hospice benefit any time during the measurement year.
- Members who die any time during the measurement year.
- Members receiving palliative care any time during the measurement year.
- Members who had an encounter for palliative care (ICD-10-CM code Z51.5) any time during the measurement year.
- Medicare members 66 years of age and older as of December 31 of the measurement year who Enrolled in an Institutional SNP or Lived long-term in an institution any time during the measurement year
- Members 66 years of age and older as of December 31 of the measurement year with frailty and advanced illness. Members must meet **both** frailty and advanced illness criteria to be excluded.

### Statin Therapy for Patients with Cardiovascular Disease (SPC) cont.

#### Claims-based for HEDIS® Pharmacy Data

#### High Intensity Statin

Atorvastatin 40-80 mg Amlodipine-atorvastatin 40-80 mg Rosuvastatin 20-40 mg Simvastatin 80 mg Ezetimibe-simvastatin 80 mg

#### **Moderate Intensity Statin**

Atorvastatin 10-20 mg Amlodipine-atorvastatin 10-20 mg Rosuvastatin 5-10 mg Simvastatin 20-40 mg Ezetimibe-simvastatin 20-40 mg Pravastatin 40-80 mg Fluvastatin 40-80 mg Pitavastatin 1–4 mg

### Statin Therapy for Patients with Cardiovascular Disease (SPC) cont.

#### Claims-based for HEDIS<sup>®</sup> Pharmacy Data Codes include but not limited to:

#### Myocardial Infarction (MI)

ICD10CM: I21.11, I21.19, I21.21, I21.29, I21.3, I21.4, I21.B, SNOMED: 194809007, 57054005, 233835003, 394710008

#### Coranary Artery Bi-Pass Graft (CABG)

CPT CODES: 33534, 33535, 33536, 33533, 33518, 33519, 33521, 33522, 33523, 33517, 33511, 33512, 33514, 33516, 33510, 33530

HCPCS: S2205, S2206, S2208, S2209, S2207

SNOMED: 175021005, 736970002, 736971003, 736972005, 736973000, 67166004, 8876004, 3546002, 405599002, 405598005,17073005, 232717009, 736962007, 736963002, 736964008, 736965009

#### Percutaneous coronary intervention (PCI)

ICD10PCS: Numerous Artery and device specific codes CPT CODES: 92928, 92920, 92924, 92933, 92941, 92943, 92937 HCPCS: C9600, C9602, C9606, C9607, C9604 SNOMED: 414089002, 36969009, 68466008 **Ischemic vascular disease (IVD)** ICD10CM:I20.0, I20.9, I25.5, I24.9, I25.6, I25.82, I25.83, I25.84, I25.85, I25.89, I25.9, I66.9, I67.2, I70.1

SNOMED: 233955003, 413439005, 413444003, 194828000, 81817003, 64586002, 432504007, 312829002

### **Cardiac Rehabilitation (CRE)**

The percentage of members 18 years and older who attended cardiac rehabilitation following a qualifying cardiac event, including myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, heart and heart/lung transplantation or heart valve repair/replacement. Four rates are reported:

- *1. <u>Initiation</u>*. The percentage of members who attended **2** or more sessions of cardiac rehabilitation within **30** days after a qualifying event.
- <u>Engagement</u> 1. The percentage of members who attended 12 or more sessions of cardiac rehabilitation within 90 days after a qualifying event.
- 3. <u>Engagement 2</u>. The percentage of members who attended **24** or more sessions of cardiac rehabilitation within **180** days after a qualifying event.
- <u>Achievement.</u> The percentage of members who attended **36** or more sessions of cardiac rehabilitation within **180** days after a qualifying event.

#### **Tips to Help Close Member Care Gaps:**

- Intake period-July 1 of the year prior to the measurement year to June 30 of the measurement year.
- Episode date- The most recent cardiac event during the intake period, including myocardial infarction (MI), coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), heart or heart/lung transplant or heart valve repair/ replacement
  - For MI, CABG, heart or heart/lung transplant or heart valve repair/replacement, the episode date is <u>the date of</u> <u>discharge</u>.
  - For PCI, the episode date is the *date of service*
  - For inpatient claims, the episode date is the *date of discharge*.
  - For direct transfers, the episode date is the *discharge date from the last admission*

### **Cardiac Rehabilitation (CRE) cont.**

**Note:** Count multiple cardiac rehabilitation sessions on the same date of service as multiple sessions. For example, if a member has two different codes for cardiac rehabilitation on the same date of service (or one code billed as two units), count this as two sessions of cardiac rehabilitation.

**Required Exclusions:** Exclude members who meet any of the following criteria:

- Discharged from an inpatient setting with any of the following on the discharge claim <u>during</u> the 180 days after the episode date:
  - ≻MI
  - ≻CABG
  - > Heart or heart/lung transplant
  - > Heart valve repair or replacement
- PCI. Members who had PCI in any setting, **during** the 180 days after the episode date.
- Members who use hospice services or elect to use a hospice benefit any time **<u>during</u>** the measurement year
- Members who die any time during the measurement year.
- Members receiving palliative care any time during the intake period through the end of the measurement year.
- Members who had an encounter for palliative care) any time during the intake period through the end of the measurement year.

### **Cardiac Rehabilitation (CRE) cont.**

#### **Required Exclusions: cont**

- Medicare members 66 years of age and older as of December 31 of the measurement year who meet either of the following:
  - > Enrolled in an Institutional SNP (I-SNP) any time during the intake period through the end of the measurement year.
  - Living long-term in an institution any time during the intake period through the end of the measurement year
- Members 66–80 years of age as of December 31 of the measurement year with frailty and advanced illness.
   Members must meet both frailty and advanced illness criteria to be excluded
- Members 81 years of age and older as of December 31 of the measurement year with at least two
  indications of frailty with different dates of service any time during the intake period through the end of
  the measurement year.

CPT Codes: 93797, 93798 HCPCS Codes: S9472, G0422, G0423 SNOMED CT CODES: 395696000, 395697009, 395698004, 395699007, 313395003, 229822009, 385979001 385980003, 24050008

# **Other Resources**

# **Documentation Best Practice Checklist**



**Annually assess** all chronic conditions and document a plan for each one

Code and document all coexisting conditions that require or affect patient care, treatment or management



**Link medications** to help establish ongoing treatment especially if the medication is used to treat multiple conditions.

 $\checkmark$ 

**Avoid using uncertain terms** when a diagnosis has been confirmed for a patient



**Use the term "History of"** before a condition if it no longer exists or has resolved

**Choose the highest level of specificity** when selecting an ICD-10 code





**Keep problem list up to date** by removing acute and one-time conditions

# **Highmark Provider Resources**

#### **KNOWLEDGE COLLEGE**

30-minute on-demand courses on risk adjustment coding and documentation to help providers comply with CMS standards and ICD-10-CM guidelines

- 1. Log into Availity.
- 2. Navigate to the Provider Resource Center.
- 3. Locate "Resources and Education" in the menu bar and navigate to "Clinical Quality & Education".
- 4. Select "Coding Education/HCC University".

### **RISK ADJUSTMENT OVERVIEW**

Review the foundations of what risk adjustment is, hierarchical condition categories, common errors, best practices and impacts to patient care



### DISEASE BURDEN CAPTURE VIDEOS

Recorded videos focusing on accurate disease burden capture of patients' complete health status to increase the quality of care that they receive



### **CODING & DOCUMENTATION CARDS**

Reference cards to assist with documentation and coding according to CMS documentation standards and ICD-10-CM coding requirements



# **Other Resources**

DoctusTech is an app that allows providers to build their knowledge on risk adjustment which assists with higher documentation specificity and accuracy in diagnosis code assignment. Providers can earn CME credit with completion of modules within the app.



Questions regarding presentation materials? Feedback on topics for upcoming sessions?

Email: <u>RiskAdjustmentCoding@Highmark.com</u>

### **Thank You!**